Guangdong Zhongsheng Pharmaceutical Co Ltd (SHE:002317) — Market Cap & Net Worth
Market Cap & Net Worth: Guangdong Zhongsheng Pharmaceutical Co Ltd (002317)
Guangdong Zhongsheng Pharmaceutical Co Ltd (SHE:002317) has a market capitalization of $3.06 Billion (CN¥20.94 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #4866 globally and #809 in its home market, demonstrating a -1.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guangdong Zhongsheng Pharmaceutical Co Ltd's stock price CN¥24.64 by its total outstanding shares 849930477 (849.93 Million). Also see Guangdong Zhongsheng Pharmaceutical Co L balance sheet assets for a full breakdown of the balance sheet.
Guangdong Zhongsheng Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Guangdong Zhongsheng Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.43 Billion to $3.06 Billion (8.07% CAGR). Also see Guangdong Zhongsheng Pharmaceutical Co L cash conversion from operations for how efficiently the company converts equity into cash flow.
Guangdong Zhongsheng Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guangdong Zhongsheng Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Guangdong Zhongsheng Pharmaceutical Co L (002317) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.61x
Guangdong Zhongsheng Pharmaceutical Co Ltd's market cap is 0.61 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.43 Billion | $1.58 Billion | $296.71 Million | 0.90x | 4.81x |
| 2016 | $1.35 Billion | $1.69 Billion | $414.37 Million | 0.80x | 3.25x |
| 2017 | $1.40 Billion | $1.96 Billion | $420.12 Million | 0.72x | 3.34x |
| 2018 | $938.53 Million | $2.36 Billion | $435.65 Million | 0.40x | 2.15x |
| 2019 | $1.46 Billion | $2.53 Billion | $317.73 Million | 0.58x | 4.60x |
| 2020 | $1.29 Billion | $1.90 Billion | -$426.61 Million | 0.68x | N/A |
| 2021 | $1.45 Billion | $2.43 Billion | $277.63 Million | 0.60x | 5.21x |
| 2022 | $3.27 Billion | $2.68 Billion | $322.05 Million | 1.22x | 10.16x |
| 2023 | $1.97 Billion | $2.61 Billion | $263.27 Million | 0.75x | 7.48x |
| 2024 | $1.51 Billion | $2.47 Billion | -$299.16 Million | 0.61x | N/A |
Competitor Companies of 002317 by Market Capitalization
Companies near Guangdong Zhongsheng Pharmaceutical Co Ltd in the global market cap rankings as of September 19, 2026. Review tangible net worth ratio of Guangdong Zhongsheng Pharmaceutical Co L to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Guangdong Zhongsheng Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
Guangdong Zhongsheng Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Guangdong Zhongsheng Pharmaceutical Co Ltd's market cap moved from $1.43 Billion to $ 3.06 Billion, with a yearly change of 8.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥3.06 Billion | +29.82% |
| 2025 | CN¥2.36 Billion | +56.21% |
| 2024 | CN¥1.51 Billion | -23.23% |
| 2023 | CN¥1.97 Billion | -39.81% |
| 2022 | CN¥3.27 Billion | +126.02% |
| 2021 | CN¥1.45 Billion | +12.20% |
| 2020 | CN¥1.29 Billion | -11.75% |
| 2019 | CN¥1.46 Billion | +55.72% |
| 2018 | CN¥938.53 Million | -33.19% |
| 2017 | CN¥1.40 Billion | +4.30% |
| 2016 | CN¥1.35 Billion | -5.55% |
| 2015 | CN¥1.43 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Guangdong Zhongsheng Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.06 Billion USD |
| MoneyControl | $3.06 Billion USD |
| MarketWatch | $3.06 Billion USD |
| marketcap.company | $3.06 Billion USD |
| Reuters | $3.06 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China. The company offers traditional Chinese medicine and chemical medicine. It also focuses on the fields of cardiovascular, respiratory, ophthalmology, and digestive. Guangdong Zhongsheng Pharmaceutical Co., Ltd. was founded in 1979 and is based in Dongguan, China.